Mario Balsa· @MarioBalsaMD · X·· 2 天前评分90
正文 · 原文
My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L.
💥 ORR: 70% vs 32.7% || mPFS: 33.0 vs 3.4 mo
▪️G3/4 TEAEs: 70% vs 39%
OS: positive trend, but immature after early trial closure.
Impressive PFS! But STARBOARD has not reached the OS shore yet⚓
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
819 浏览 · 9 赞 · 7 转发 · 0 回复
会议摘要
2071O按 Proffered paper: Melanoma and other skin tumours 对上
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.org来源：Mario Balsa · x.com